First Wave BioPharma announces publication of two patent applications

First Wave BioPharma announced the publication of two patent applications for composition of matter and methods of use claims governing the Company’s enhanced enteric microgranule delivery formulation of adrulipase. The two applications were published by both the United States Patent and Trademark Office, USPTO, and the International Bureau of the World International Patent Organization, WIPO, under the Patent Cooperation Treaty, PCT. The PCT includes 157 countries and covers virtually all worldwide industrialized markets. “The patent publications for our enhanced enteric microgranule delivery formulation of adrulipase and its use for the treatment of malabsorption highlight First Wave’s ability to introduce important drug innovations for the treatment of underserved disease indications,” said James Sapirstein, President and CEO of First Wave BioPharma. “Possessing multilayered IP for our drug technologies is an important value driver for First Wave and is a key component of our business strategy as we await topline data from the Phase 2 SPAN clinical trial investigating our enhanced enteric microgranule delivery formulation of adrulipase.”